<?xml version="1.0" encoding="UTF-8"?>
<ref id="B63">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Folegatti</surname>
    <given-names>P. M.</given-names>
   </name>
   <name>
    <surname>Bellamy</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Flaxman</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Mair</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Ellis</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Ramon</surname>
    <given-names>R. L.</given-names>
   </name>
   <etal/>
  </person-group>. (
  <year>2019</year>). 
  <article-title>Safety and immunogenicity of the heterosubtypic influenza A vaccine MVA-NP+M1 mnufactured on the AGE1.CR.pIX avian cell line</article-title>. 
  <source>Vaccines</source>
  <volume>7</volume>:
  <fpage>33</fpage>. 
  <pub-id pub-id-type="doi">10.3390/vaccines7010033</pub-id>
  <?supplied-pmid 30909516?>
  <pub-id pub-id-type="pmid">30909516</pub-id>
 </mixed-citation>
</ref>
